Hematopoietic Stem Cell TransplantationTransplantation, HomologousBone Marrow TransplantationGraft vs Host DiseaseStem Cell TransplantationTransplantation ConditioningHematologic NeoplasmsTransplantation, AutologousHematopoietic Stem CellsTransplantation ChimeraPeripheral Blood Stem Cell TransplantationTissue DonorsGraft vs Leukemia EffectBusulfanTreatment OutcomeWhole-Body IrradiationBone MarrowLeukemiaMyeloablative AgonistsRecurrenceStem CellsGraft SurvivalHistocompatibility TestingGraft vs Tumor EffectBone Marrow CellsHistocompatibilityRemission InductionRetrospective StudiesVidarabineLeukemia, Myeloid, AcuteChimerismImmunosuppressive AgentsLymphocyte TransfusionCord Blood Stem Cell TransplantationMyelodysplastic SyndromesHematologic DiseasesAnemia, AplasticLeukemia, Myelogenous, Chronic, BCR-ABL PositivePrecursor Cell Lymphoblastic Leukemia-LymphomaCombined Modality TherapySiblingsLiver TransplantationCytomegalovirus InfectionsHepatic Veno-Occlusive DiseaseSurvival AnalysisHLA AntigensTime FactorsSurvival RateT-LymphocytesLymphocyte DepletionMultiple MyelomaCyclophosphamideDisease-Free SurvivalAcute DiseaseTransplantation ImmunologyMinor Histocompatibility AntigensTransplantation, IsogeneicHematopoiesisSalvage TherapyAntilymphocyte SerumHematopoietic Stem Cell MobilizationNeoplasm, ResidualAllograftsBlood CellsAntigens, CD34Flow CytometryFollow-Up StudiesLeukemia, MyeloidKidney TransplantationAntineoplastic Combined Chemotherapy ProtocolsMice, Inbred C57BLImmunosuppressionCytomegalovirusOpportunistic InfectionsLymphoproliferative DisordersMelphalanSevere Combined ImmunodeficiencyPrognosisCell DifferentiationGraft RejectionMesenchymal Stem Cell TransplantationCell TransplantationImmunocompromised HostPrimary MyelofibrosisCytarabineFatal OutcomeVirus ActivationGranulocyte Colony-Stimulating FactorCyclosporineRisk FactorsCells, CulturedCystitisLymphoma, Non-HodgkinGanciclovirLeukemic InfiltrationAntineoplastic AgentsHeart TransplantationProspective StudiesMycosesEmbryonic Stem Cells